211 related articles for article (PubMed ID: 24074843)
1. Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.
Felts AS; Rodriguez AL; Morrison RD; Venable DF; Manka JT; Bates BS; Blobaum AL; Byers FW; Daniels JS; Niswender CM; Jones CK; Conn PJ; Lindsley CW; Emmitte KA
Bioorg Med Chem Lett; 2013 Nov; 23(21):5779-85. PubMed ID: 24074843
[TBL] [Abstract][Full Text] [Related]
2. Discovery of VU0431316: a negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.
Bates BS; Rodriguez AL; Felts AS; Morrison RD; Venable DF; Blobaum AL; Byers FW; Lawson KP; Daniels JS; Niswender CM; Jones CK; Conn PJ; Lindsley CW; Emmitte KA
Bioorg Med Chem Lett; 2014 Aug; 24(15):3307-14. PubMed ID: 24969015
[TBL] [Abstract][Full Text] [Related]
3. Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles.
Rook JM; Tantawy MN; Ansari MS; Felts AS; Stauffer SR; Emmitte KA; Kessler RM; Niswender CM; Daniels JS; Jones CK; Lindsley CW; Conn PJ
Neuropsychopharmacology; 2015 Feb; 40(3):755-65. PubMed ID: 25241804
[TBL] [Abstract][Full Text] [Related]
4. The role of aldehyde oxidase and xanthine oxidase in the biotransformation of a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5.
Morrison RD; Blobaum AL; Byers FW; Santomango TS; Bridges TM; Stec D; Brewer KA; Sanchez-Ponce R; Corlew MM; Rush R; Felts AS; Manka J; Bates BS; Venable DF; Rodriguez AL; Jones CK; Niswender CM; Conn PJ; Lindsley CW; Emmitte KA; Daniels JS
Drug Metab Dispos; 2012 Sep; 40(9):1834-45. PubMed ID: 22711749
[TBL] [Abstract][Full Text] [Related]
5. Identification of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Acting at Site Distinct from 2-Methyl-6-(phenylethynyl)-pyridine Binding.
Butkiewicz M; Rodriguez AL; Rainey SE; Wieting J; Luscombe VB; Stauffer SR; Lindsley CW; Conn PJ; Meiler J
ACS Chem Neurosci; 2019 Aug; 10(8):3427-3436. PubMed ID: 31132237
[TBL] [Abstract][Full Text] [Related]
6. Discovery of (1R,2R)-N-(4-(6-isopropylpyridin-2-yl)-3-(2-methyl-2H-indazol-5-yl)isothiazol-5-yl)-2-methylcyclopropanecarboxamide, a potent and orally efficacious mGlu5 receptor negative allosteric modulator.
Hao J; Dehlinger V; Fivush AM; Rudyk HC; Britton TC; Hollinshead SP; Vokits BP; Clark BP; Henry SS; Massey SM; Peng L; Dressman BA; Heinz BA; Roberts EF; Bracey-Walker MR; Swanson S; Catlow JT; Love PL; Tepool AD; Peters SC; Simmons RM; Iyengar S; McKinzie DL; Monn JA
Bioorg Med Chem Lett; 2013 Mar; 23(5):1249-52. PubMed ID: 23374867
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 6-(pyrimidin-5-ylmethyl)quinoline-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.
Felts AS; Rodriguez AL; Morrison RD; Blobaum AL; Byers FW; Daniels JS; Niswender CM; Conn PJ; Lindsley CW; Emmitte KA
Bioorg Med Chem Lett; 2018 Jun; 28(10):1679-1685. PubMed ID: 29705142
[TBL] [Abstract][Full Text] [Related]
8. VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy.
Nickols HH; Yuh JP; Gregory KJ; Morrison RD; Bates BS; Stauffer SR; Emmitte KA; Bubser M; Peng W; Nedelcovych MT; Thompson A; Lv X; Xiang Z; Daniels JS; Niswender CM; Lindsley CW; Jones CK; Conn PJ
J Pharmacol Exp Ther; 2016 Jan; 356(1):123-36. PubMed ID: 26503377
[TBL] [Abstract][Full Text] [Related]
9. Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology.
Sengmany K; Hellyer SD; Albold S; Wang T; Conn PJ; May LT; Christopoulos A; Leach K; Gregory KJ
Neuropharmacology; 2019 May; 149():83-96. PubMed ID: 30763654
[TBL] [Abstract][Full Text] [Related]
10. Insights into the interaction of negative allosteric modulators with the metabotropic glutamate receptor 5: discovery and computational modeling of a new series of ligands with nanomolar affinity.
Anighoro A; Graziani D; Bettinelli I; Cilia A; De Toma C; Longhi M; Mangiarotti F; Menegon S; Pirona L; Poggesi E; Riva C; Rastelli G
Bioorg Med Chem; 2015 Jul; 23(13):3040-58. PubMed ID: 26014480
[TBL] [Abstract][Full Text] [Related]
11. Partial mGlu₅ Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects.
Gould RW; Amato RJ; Bubser M; Joffe ME; Nedelcovych MT; Thompson AD; Nickols HH; Yuh JP; Zhan X; Felts AS; Rodriguez AL; Morrison RD; Byers FW; Rook JM; Daniels JS; Niswender CM; Conn PJ; Emmitte KA; Lindsley CW; Jones CK
Neuropsychopharmacology; 2016 Mar; 41(4):1166-78. PubMed ID: 26315507
[TBL] [Abstract][Full Text] [Related]
12. Fused thiazolyl alkynes as potent mGlu5 receptor positive allosteric modulators.
Packiarajan M; Grenon M; Zorn S; Hopper AT; White AD; Chandrasena G; Pu X; Brodbeck RM; Robichaud AJ
Bioorg Med Chem Lett; 2013 Jul; 23(14):4037-43. PubMed ID: 23770058
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 4-alkoxy-6-methylpicolinamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.
Felts AS; Bollinger KA; Brassard CJ; Rodriguez AL; Morrison RD; Scott Daniels J; Blobaum AL; Niswender CM; Jones CK; Conn PJ; Emmitte KA; Lindsley CW
Bioorg Med Chem Lett; 2019 Jan; 29(1):47-50. PubMed ID: 30446311
[TBL] [Abstract][Full Text] [Related]
14. mGlu5-dependent modulation of anxiety during early withdrawal from binge-drinking in adult and adolescent male mice.
Lee KM; Coelho MA; Class MA; Szumlinski KK
Drug Alcohol Depend; 2018 Mar; 184():1-11. PubMed ID: 29324247
[TBL] [Abstract][Full Text] [Related]
15. Mechanism based neurotoxicity of mGlu5 positive allosteric modulators--development challenges for a promising novel antipsychotic target.
Parmentier-Batteur S; Hutson PH; Menzel K; Uslaner JM; Mattson BA; O'Brien JA; Magliaro BC; Forest T; Stump CA; Tynebor RM; Anthony NJ; Tucker TJ; Zhang XF; Gomez R; Huszar SL; Lambeng N; Fauré H; Le Poul E; Poli S; Rosahl TW; Rocher JP; Hargreaves R; Williams TM
Neuropharmacology; 2014 Jul; 82():161-73. PubMed ID: 23291536
[TBL] [Abstract][Full Text] [Related]
16. Detailed In Vitro Pharmacological Characterization of Clinically Tested Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5.
Arsova A; Møller TC; Vedel L; Hansen JL; Foster SR; Gregory KJ; Bräuner-Osborne H
Mol Pharmacol; 2020 Jul; 98(1):49-60. PubMed ID: 32358164
[TBL] [Abstract][Full Text] [Related]
17. Subtype-selective mechanisms of negative allosteric modulators binding to group I metabotropic glutamate receptors.
Fu TT; Tu G; Ping M; Zheng GX; Yang FY; Yang JY; Zhang Y; Yao XJ; Xue WW; Zhu F
Acta Pharmacol Sin; 2021 Aug; 42(8):1354-1367. PubMed ID: 33122823
[TBL] [Abstract][Full Text] [Related]
18. 3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure in rats.
Felts AS; Lindsley SR; Lamb JP; Rodriguez AL; Menon UN; Jadhav S; Jones CK; Conn PJ; Lindsley CW; Emmitte KA
Bioorg Med Chem Lett; 2010 Aug; 20(15):4390-4. PubMed ID: 20598884
[TBL] [Abstract][Full Text] [Related]
19. Identification and optimisation of a series of tetrahydrobenzotriazoles as metabotropic glutamate receptor 5-selective positive allosteric modulators that improve performance in a preclinical model of cognition.
Ellard JM; Madin A; Philps O; Hopkin M; Henderson S; Birch L; O'Connor D; Arai T; Takase K; Morgan L; Reynolds D; Talma S; Howley E; Powney B; Payne AH; Hall A; Gartlon JE; Dawson LA; Castro L; Atkinson PJ
Bioorg Med Chem Lett; 2015 Dec; 25(24):5792-6. PubMed ID: 26531152
[TBL] [Abstract][Full Text] [Related]
20. Structure-based discovery and development of metabotropic glutamate receptor 5 negative allosteric modulators.
Bennett KA; Christopher JA; Tehan BG
Adv Pharmacol; 2020; 88():35-58. PubMed ID: 32416871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
